Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Rhea-AI Summary
Cryoport (NASDAQ: CYRX) launched the MVE Fusion® 800 Series, a lab-sized self-sustaining cryogenic freezer designed for space-constrained environments. The Fusion 800 eliminates the need for a continuous liquid nitrogen supply, delivers steady-state temperatures at or below -150°C, and fits through standard doorways at 32 inches wide. The technology is ISBER award-winning and aimed at research facilities, hospital pharmacies, biorepositories, and blood and tissue banks.
Positive
- Eliminates continuous LN₂ supply, reducing reliance on external liquid nitrogen infrastructure
- Maintains steady-state temperatures ≤ -150°C suitable for critical biological materials
- Compact 32-inch width fits through standard doorways enabling installation without facility modification
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Pre-news move in CYRX of +1.05% occurred without broad peer confirmation; only one momentum peer (BTOC) was up and no close logistics peers showed a consistent direction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 earnings | Positive | +2.0% | Revenue growth and raised full‑year guidance with improved margins and liquidity. |
| Oct 30 | Operational certification | Positive | -2.6% | ISO 21973:2020 certification and industry award for supply chain excellence. |
| Oct 21 | Earnings call notice | Neutral | -3.7% | Announcement of timing and access details for upcoming Q3 2025 results call. |
Earnings-related updates have previously seen modest positive alignment, while operational and certification news have shown mixed or negative short-term reactions.
Over the last few months, Cryoport reported Q3 2025 revenue of $44.2M (up 15% year‑over‑year) and raised full‑year revenue guidance to $170.0–$174.0M, with a positive +1.99% price reaction. Operationally, the company highlighted ISO 21973:2020 certification and supply chain accolades, which coincided with a -2.6% move. An earlier notice about the upcoming Q3 2025 earnings call saw a -3.7% reaction. Today’s new Fusion 800 product launch fits the pattern of operational/product news layered on top of a strengthening financial base.
Market Pulse Summary
This announcement highlights the launch of the MVE Fusion 800, a self-sustaining cryogenic freezer aimed at space‑constrained labs and pharmacies, operating at or below -150°C and only 32 inches wide. It follows Q3 2025 revenue of $44.2M and liquidity of $421.314M, plus ISO 21973:2020 certification and supply‑chain awards. Investors may watch for evidence of customer adoption, pricing, and how this product contributes to Life Sciences Products growth over time.
Key Terms
cryogenic freezer technical
cryogenic storage technical
AI-generated analysis. Not financial advice.
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility,
and Cost Benefits in Limited Space Environments
Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted performance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly facility modifications.
"The Fusion 800 is a major evolution and a step forward into the future," said Mike Duich, President and CEO of MVE Biological Solutions. "Fusion 800 delivers the storage density, flexibility, and operational freedom our customers demand without the infrastructure burden of traditional cryogenic systems. This product opens the door for more facilities to safely adopt true cryogenic storage."
"Truly transformative products are rare in this industry, but the MVE Fusion 800 is one of them," said Jerrell Shelton, CEO of Cryoport. "It solves a longstanding challenge in cryogenic storage by protecting critical biological materials and life-saving therapies without the space and infrastructure requirements of legacy cryogenic storage systems. We believe the Fusion 800 is on a path to becoming the new standard in research facilities and hospital pharmacies worldwide."
Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C.
For more information on the MVE Fusion® 800 Series, visit: https://mvebio.com/ or consult with an MVE distributor.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-introduces-new-fusion-800-series-302684810.html
SOURCE Cryoport, Inc.
FAQ
What is the MVE Fusion 800 launched by Cryoport (CYRX) on Feb 11, 2026?
How cold does the Cryoport MVE Fusion 800 (CYRX) operate for storing biological materials?
Does the MVE Fusion 800 from Cryoport (CYRX) require liquid nitrogen hookups?
What facilities is Cryoport targeting with the MVE Fusion 800 (CYRX)?
What recognition has the Fusion technology earned and how does that apply to the Fusion 800 (CYRX)?
